Tranquis is an early-stage biotechnology company founded on cutting-edge neuro-immunology research from the laboratory of Prof. Edgar G. Engleman at Stanford University, which shows that altered metabolism of myeloid immune cells underlies a variety of central nervous system (CNS) disorders, including Amyotrophic Lateral Sclerosis, Parkinson’s Disease, Alzheimer’s Disease, and age-related neuropathology.
